N-Allylcyclohexylamine → N-Allyl-N-cyclohexyl-2-[4-(3,3-diphenyl-1-propyl)piperazin-1-yl]-5-methylisonicotinamide

HRID 1796759

반응식

HRID 1796759 반응식
[C:1]1([CH:7]([C:26]2[CH:31]=[CH:30][CH:29]=[CH:28][CH:27]=2)[CH2:8][CH2:9][N:10]2[CH2:15][CH2:14][N:13]([C:16]3[CH:17]=[C:18]([C:22]([CH3:25])=[CH:23][N:24]=3)[C:19](O)=[O:20])[CH2:12][CH2:11]2)[CH:6]=[CH:5][CH:4]=[CH:3][CH:2]=1.[CH2:32]([NH:35][CH:36]1[CH2:41][CH2:40][CH2:39][CH2:38][CH2:37]1)[CH:33]=[CH2:34]>>[CH2:32]([N:35]([CH:36]1[CH2:41][CH2:40][CH2:39][CH2:38][CH2:37]1)[C:19](=[O:20])[C:18]1[C:22]([CH3:25])=[CH:23][N:24]=[C:16]([N:13]2[CH2:14][CH2:15][N:10]([CH2:9][CH2:8][CH:7]([C:1]3[CH:2]=[CH:3][CH:4]=[CH:5][CH:6]=3)[C:26]3[CH:31]=[CH:30][CH:29]=[CH:28][CH:27]=3)[CH2:11][CH2:12]2)[CH:17]=1)[CH:33]=[CH2:34]

참가 물질

3

반응물 2

HCID 81115N-AllylcyclohexylamineHCID 221806402-[4-(3,3-Diphenyl-1-propyl)piperazin-1-yl]-5-methylisonicotinic acid

생성물 1

HCID 22180511N-Allyl-N-cyclohexyl-2-[4-(3,3-diphenyl-1-propyl)piperazin-1-yl]-5-methylisonicotinamide수율 72.8%

실험 절차

Step (d) of Example 107 was repeated, except that the compound (50 mg) prepared in step (d) of Example 108 and allylcyclohexylamine (34 mg) were used as the starting compounds. Thus, the title compound (47 mg) was obtained.

출처 및 근거

ORD 기록
ord-8e757de0a427484089bebbeffbfb2f9f
출처 데이터셋
uspto-grants-2006_04
특허 번호
US07030120B2

연결된 노트

불러오는 중…